AVEO Pharmaceuticals, Inc. (AVEO): Price and Financial Metrics

AVEO Pharmaceuticals, Inc. (AVEO): $6.91

0.27 (+4.07%)

POWR Rating

Component Grades













Add AVEO to Watchlist
Sign Up

Industry: Biotech


of 484

in industry


  • Value is the dimension where AVEO ranks best; there it ranks ahead of 58.64% of US stocks.
  • AVEO's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • AVEO ranks lowest in Stability; there it ranks in the 2nd percentile.

AVEO Stock Summary

  • With a one year PEG ratio of 0.2, Aveo Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 1.5% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Aveo Pharmaceuticals Inc is reporting a growth rate of -2,450.05%; that's higher than just 0.67% of US stocks.
  • Revenue growth over the past 12 months for Aveo Pharmaceuticals Inc comes in at -74.42%, a number that bests just 2.99% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Aveo Pharmaceuticals Inc, a group of peers worth examining would be FSLR, AEHR, ARW, SDPI, and KNDI.
  • Visit AVEO's SEC page to see the company's official filings. To visit the company's web site, go to www.aveooncology.com.

AVEO Price Target

For more insight on analysts targets of AVEO, see our AVEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.00 Average Broker Recommendation 1.12 (Strong Buy)

AVEO Stock Price Chart Interactive Chart >

Price chart for AVEO

AVEO Price/Volume Stats

Current price $6.91 52-week high $18.24
Prev. close $6.64 52-week low $4.07
Day low $6.64 Volume 517,832
Day high $6.92 Avg. volume 1,639,302
50-day MA $6.88 Dividend yield N/A
200-day MA $6.93 Market Cap 237.43M

AVEO Pharmaceuticals, Inc. (AVEO) Company Bio

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

AVEO Latest News Stream

Event/Time News Detail
Loading, please wait...

AVEO Latest Social Stream

Loading social stream, please wait...

View Full AVEO Social Stream

Latest AVEO News From Around the Web

Below are the latest news stories about Aveo Pharmaceuticals Inc that investors may wish to consider to help them evaluate AVEO as an investment opportunity.

AVEO Oncology: Time To Be Patient

Photo by wildpixel/iStock via Getty Images After years of setbacks, 2021 has been a transformative year for AVEO Oncology (AVEO) and its investors. The company’s flagship product, FOTIVDA, was finally approved by the FDA and the company launched the product soon after. Recently, AVEO provided us with some fresh launch...

Biologics on Seeking Alpha | June 7, 2021

AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investigational potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF), being studied in head and neck squamous cell carcinoma (HNSCC) on Wednesday, June 16, 2021 at 2:00 p.m. Eastern Time.

Yahoo | June 7, 2021

AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time.

Yahoo | May 25, 2021

10 “Strong Buy” Healthcare Stocks With Over 100% Upside Potential According to Top Analysts

With so many people giving investment advice online, it can seem that you only need an email address to become a financial influencer. Meanwhile, financial analysts with a proven track record carefully research companies and produce detailed reports with their recommendations and reasoning behind them. The TipRanks stock screener enables investors to easily search for stocks according to different criteria. These include the analyst consensus and price targets of the top-performing Wall Street analysts. We used it to search for stocks with the highest upside potential as we head towards May 2021.

Varda Bachrach on TipRanks | April 27, 2021

Earnings Preview: AVEO Pharmaceuticals (AVEO) Q1 Earnings Expected to Decline

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | April 22, 2021

Read More 'AVEO' Stories Here

AVEO Price Returns

1-mo 1.32%
3-mo -33.62%
6-mo 34.17%
1-year 33.14%
3-year -69.83%
5-year -32.25%
YTD 19.76%
2020 -7.58%
2019 -60.98%
2018 -42.65%
2017 416.67%
2016 -57.14%

Continue Researching AVEO

Here are a few links from around the web to help you further your research on Aveo Pharmaceuticals Inc's stock as an investment opportunity:

Aveo Pharmaceuticals Inc (AVEO) Stock Price | Nasdaq
Aveo Pharmaceuticals Inc (AVEO) Stock Quote, History and News - Yahoo Finance
Aveo Pharmaceuticals Inc (AVEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8262 seconds.